Abstract:BACKGROUND & AIMS Immune checkpoint inhibitors have limited efficacy in many tumors. We investigated mechanisms of tumor resistance to inhibitors of programmed cell death 1 (PDCD1, also called PD1) in mice with gastric cancer, and the role of its ligand, PDL1. METHODS Gastrin-deficient mice were given N-methyl-N-nitrosourea (MNU) in drinking water along with Helicobacter felis to induce gastric tumor formation; we also performed studies with H/K-ATPase-hIL1B mice, which develop spontaneous gastric tumors at the antral-corpus junction and have parietal cells that constitutively secrete IL1B. Mice were given injections of an antibody against PD1 or an isotype control before tumors developed, or anti-PD1 and 5-fluorouracil and oxaliplatin, or an antibody against lymphocyte antigen 6 complex locus G (also called Gr-1), which depletes myeloid-derived suppressor cells [MDSCs]), after tumors developed. We generated knockin mice that express PDL1 specifically in the gastric epithelium or myeloid lineage. RESULTS When given to gastrin-deficient mice before tumors grew, anti-PD1 significantly reduced tumor size and increased tumor infiltration by T cells. However, anti-PD1 alone did not have significant effects on established tumors in these mice. Neither early nor late anti-PD1 administration reduced tumor growth in the presence of MDSCs in H/K-ATPase-hIL1B mice. The combination of 5-fluorouracil and oxaliplatin reduced MDSCs, increased numbers of intra-tumor CD8+ T cells, and increased the response of tumors to anti-PD1-however, this resulted in increased tumor expression of PDL1. Expression of PDL1 by tumor or immune cells increased gastric tumorigenesis in mice given MNU. Mice with gastric epithelial cells that expressed PDL1 did not develop spontaneous tumors, but they developed more and larger tumors after administration of MNU and H. felis, with accumulation of MDSCs. CONCLUSIONS In mouse models of gastric cancer, 5-fluorouracil and oxaliplatin reduce numbers of MDSCs to increase the effects of anti-PD1, which promotes tumor infiltration by CD8+ T cells. However, these chemotherapeutic agents also induce expression of PDL1 by tumor cells. Expression of PDL1 by gastric epithelial cells increases tumorigenesis in response to MNU and H. felis, and accumulation of MDSCs, which promote tumor progression. The timing and site of PDL1 expression is therefore important in gastric tumorigenesis and should be considered in design of therapeutic regimens.

Knockdown of PD-L1 in Human Gastric Cancer Cells Inhibits Tumor Progression and Improves the Cytotoxic Sensitivity to CIK Therapy.

PD-L1 and Gastric Cancer Prognosis: A Systematic Review and Meta-Analysis

Effects of Lncrna ANRIL-knockdown on the Proliferation, Apoptosis and Cell Cycle of Gastric Cancer Cells.

PD-L1 Expression and Its Effect on Clinical Outcomes of EGFR-mutant NSCLC Patients Treated with EGFR-TKIs

Programmed Cell Death Ligand 1 (PD-L1) Expression on Gastric Cancer and Its Relationship with Clinicopathologic Factors.

Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications.

PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice.

Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival

MicroRNA-375 Reverses the Expression of PD-L1 by Inactivating the JAK2/STAT3 Signaling Pathways in Gastric Cancer

Knockdown of a Proliferation-Inducing Ligand (PRIL) Suppresses the Proliferation of Gastric Cancer Cells.

Association between PD-L1 Expression on Tumour-Infiltrating Lymphocytes and Overall Survival in Patients with Gastric Cancer.

Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance.

PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer

Nanoparticle-Delivered Transforming Growth Factor-β1 siRNA Induces PD-1 against Gastric Cancer by Transforming the Phenotype of the Tumor Immune Microenvironment

Irgd Enhances T Cells Infiltration and Augments Response to PD-1 Gene Knockout Immunotherapy in Gastric Cancer

Expression and clinical significance of PD-L1 and infiltrated immune cells in the gastric adenocarcinoma microenvironment

Prevalence of Programmed Death-1 Ligand-1 (PD-L1) and Infiltrating Lymphocytes in Human Gastric Carcinogenesis

PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer

PD-1/PD-L Blockade in Gastrointestinal Cancers: Lessons Learned and the Road Toward Precision Immunotherapy

miR-502-5p affects gastric cancer progression by targeting PD-L1

Integrated Assessment of PD-L1 Expression and Molecular Classification Facilitates Therapy Selection and Prognosis Prediction in Gastric Cancer